SuperworthEli Lilly and EPS LLY
Diluted earnings per share by quarter and over the last twelve months, from 1995.
- Last 12 months, to Jun 30, 2026
- $29.80
- Latest quarter, Q2 FY26
- $7.94
- +26% on a year earlier
- Fiscal year 2025
- $22.95
- +96% on the year before
Eli Lilly and's earnings per share was $29.80 over the twelve months to Jun 30, 2026, up 95% on a year earlier.
In its latest quarter, Q2 FY26, it was $7.94, up 26% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 28% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $22.95 | +96% |
| FY2024 | $11.71 | +102% |
| FY2023 | $5.80 | −16% |
| FY2022 | $6.90 | +12% |
| FY2021 | $6.14 | −10% |
| FY2020 | $6.80 | −22% |
| FY2019 | $8.75 | +180% |
| FY2018 | $3.13 | n/a |
| FY2017 | −$0.21 | −108% |
| FY2016 | $2.58 | +14% |
| FY2015 | $2.26 | +1% |
| FY2014 | $2.23 | −48% |
| FY2013 | $4.31 | +18% |
| FY2012 | $3.66 | −6% |
| FY2011 | $3.90 | −15% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $7.94 | +26% | $29.80 | |
| Q1 FY26 | $8.26 | +170% | $28.15 | |
| Q4 FY25 | $7.39 | +51% | $22.95 | |
| Q3 FY25 | $6.21 | +480% | $20.44 | |
| Q2 FY25 | $6.29 | +92% | $15.30 | |
| Q1 FY25 | $3.06 | +23% | $12.29 | |
| Q4 FY24 | $4.88 | +102% | $11.71 | |
| Q3 FY24 | $1.07 | n/a | $9.25 | |
| Q2 FY24 | $3.28 | +68% | $8.12 | |
| Q1 FY24 | $2.48 | +66% | $6.79 | |
| Q4 FY23 | $2.42 | +13% | $5.80 | |
| Q3 FY23 | −$0.06 | −104% | $5.52 |
Against its peers
Companies in Drug Manufacturers - General nearest Eli Lilly and's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| LLYEli Lilly and | $29.80 | +95% a year |
| JNJJohnson & Johnson | $6.60 | −36% a year |
| ABBVAbbVie | $3.54 | +69% a year |
| MRKMerck | $1.25 | −81% a year |
| AMGNAmgen | $16.09 | +32% a year |
| GILDGilead Sciences | −$2.67 | −153% a year |
| PFEPfizer | $0.76 | −60% a year |
| BMYBristol-Myers Squibb | $4.54 | +83% a year |
| Peer median | $3.54 |
Where Eli Lilly and ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Eli Lilly and
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.